ALNY
Alnylam Pharmaceuticals Inc
NASDAQ: ALNY · HEALTHCARE · BIOTECHNOLOGY
$309.49
+2.76% today
Updated 2026-04-30
Market cap
$40.19B
P/E ratio
129.82
P/S ratio
10.82x
EPS (TTM)
$2.32
Dividend yield
—
52W range
$246 – $496
Volume
1.1M
Alnylam Pharmaceuticals Inc (ALNY) Financial statements
SEC filings — annual and quarterly data.
Profit margin
8.45%
Operating margin
12.00%
ROE
73.30%
ROA
6.81%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $26.93M | $-34.61M | 100.00% | -146.68% | -128.51% |
| 2007 | $50.90M | $-85.47M | 100.00% | -183.07% | -167.92% |
| 2008 | $96.16M | $-26.25M | 100.00% | -28.95% | -27.30% |
| 2009 | $100.53M | $-47.59M | 100.00% | -47.86% | -47.34% |
| 2010 | $100.04M | $-43.52M | 100.00% | -44.05% | -43.50% |
| 2011 | $82.76M | $-57.65M | 100.00% | -66.24% | -69.66% |
| 2012 | $66.72M | $-106.01M | 100.00% | -194.01% | -158.88% |
| 2013 | $47.17M | $-89.22M | 100.00% | -197.05% | -189.17% |
| 2014 | $50.56M | $-360.39M | 100.00% | -800.97% | -712.79% |
| 2015 | $41.10M | $-290.07M | 100.00% | -720.27% | -705.83% |
| 2016 | $47.16M | $-410.11M | 100.00% | -900.33% | -869.63% |
| 2017 | $89.91M | $-490.87M | 100.00% | -556.20% | -545.95% |
| 2018 | $74.91M | $-761.50M | 97.59% | -1,087.56% | -1,016.58% |
| 2019 | $219.75M | $-886.12M | 88.60% | -427.50% | -403.24% |
| 2020 | $492.85M | $-858.28M | 84.16% | -168.09% | -174.15% |
| 2021 | $844.29M | $-852.82M | 83.40% | -83.93% | -101.01% |
| 2022 | $1.04B | $-1.13B | 83.73% | -75.68% | -109.04% |
| 2023 | $1.83B | $-440.24M | 83.02% | -15.43% | -24.08% |
| 2024 | $2.25B | $-278.16M | 85.62% | -7.87% | -12.37% |
| 2025 | $3.71B | $313.75M | 81.77% | 13.51% | 8.45% |